Dr Reddy's bets on generic semaglutide, biosimilars
Dr Reddy's domestic formulations business grew in the September quarter, while Revlimid sales declined in North America. A relaunch of generic semaglutide and the US launch of abatacept biosimilar are anticipated for future growth. The company aims to sell millions of pens for semaglutide with a focus on international markets. Furthermore, an expanding biosimilars portfolio aims...
Key Takeaways
- Dr Reddy's domestic formulations business grew in the September quarter, while Revlimid sales declined in North America.
- A relaunch of generic semaglutide and the US launch of abatacept biosimilar are anticipated for future growth.
- The company aims to sell millions of pens for semaglutide with a focus on international markets.
Dr Reddy's domestic formulations business grew in the September quarter, while Revlimid sales declined in North America. A relaunch of generic semaglutide and the US launch of abatacept biosimilar are anticipated for future growth. The company aims to sell millions of pens for semaglutide with a focus on international markets. Furthermore, an expanding biosimilars portfolio aims to strengthen its position beyond traditional generics.
Original Publisher Attribution
This summary was curated from Economic Times.